{"id":5947,"date":"2021-06-26T05:45:14","date_gmt":"2021-06-26T05:45:14","guid":{"rendered":"https:\/\/hamslivenews.com\/?p=5947"},"modified":"2021-06-26T06:14:31","modified_gmt":"2021-06-26T06:14:31","slug":"excited-to-witness-the-first-batch-of-covovax-says-adar-poonawalla","status":"publish","type":"post","link":"https:\/\/www.hamslive.com\/news\/2021\/06\/excited-to-witness-the-first-batch-of-covovax-says-adar-poonawalla\/","title":{"rendered":"Excited to witness the first batch of Covovax says Adar Poonawalla"},"content":{"rendered":"

SII manufacturing first batch of Novavax’s COVID-19 vaccine Covovax, says Adar Poonawalla, hoping to launch by September this year.<\/h1>\n

In March, Poonawalla had announced that the clinical trials of the Covovax vaccine have started in India and the company expects to launch it by September this year<\/p>\n

\n

The first batch of Covovax, a COVID-19<\/a><\/span>\u00a0vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India’s Pune facility, SII CEO Adar Poonawalla said on Friday.<\/p>\n

\n

Excited to witness the first batch of Covovax (developed by @Novavax<\/a>) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team\u00a0@seruminstindia<\/a>!\u00a0pic.twitter.com\/K4YzY6o73A<\/a><\/p>\n

\u2014 Adar Poonawalla (@adarpoonawalla)\u00a0June 25, 2021<\/a><\/p><\/blockquote>\n

Earlier in August 2020, American vaccine company Novavax Inc had declared a license agreement with SII for the development and commercialization of NVX-CoV2373, its COVID-19<\/a><\/span>\u00a0vaccine candidate, in low and middle-income countries and India.<\/p>\n

In January this year, the Serum Institute had commenced the Covishield vaccine in India and entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.<\/p>\n

He also said,\u201cExcited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia! (sic),\u201d said SII CEO Adar Poonawalla in a Twitter post on Friday.\u00a0 The US biotechnology company Novavax\u2019s protein-based vaccine, NVX-CoV2373, has confirmed 100% protection against moderate and severe disease, and 90.4% overall efficacy, in its Phase 3 trial.<\/p>\n

The Serum Institute of India stated on Friday that it has begun the production of the first batch of Novavax\u2019s Covid-19 vaccine, which will be locally manufactured under the brand name Covovax, calling it \u201ca new milestone\u201d.<\/p>\n

The Centre, too, termed the vaccine efficacy trial promising.<\/p>\n

\u201cWhat we\u2019re learning from data available in the public domain that this vaccine is very safe and highly effective,\u201d said Dr VK Paul, member-health, Niti Aayog said earlier this month.<\/p>\n

So far, three vaccines \u2014 Bharat Biotech\u2019s Covaxin, the SII\u2019s Covishield and Russia\u2019s Sputnik V \u2014 have been cleared by the Indian government.<\/p>\n

Adar Poonawalla (born 14 January 1981) is the chief executive officer (CEO) of Serum Institute of India.[1] Founded in 1966 by his father, Cyrus Poonawalla, it is the world’s largest vaccine manufacturer by the number of doses produced.<\/p>\n<\/div>\n

\n\t\t\t
\n\t\t\t <\/div><\/div>\n\t\t